L’IRM du cancer de la prostate : un changement de paradigme

MRI and prostate cancer: a paradigm shift A shift in the use of prostate MR for diagnosis, staging, and pre-treatment planning over the last several years has modified the MR protocols. Classically used to detect extra-prostatic tumor, MR now plays a role for diagnosis (pre-biopsy evaluation in a patient with elevated PSA and suspected cancer in an unusual site), treatment planning (prostate mapping), and follow-up after treatment (evaluation for local recurrence or follow-up after HIFU, radiation therapy, or focal treatment…). Imaging protocols at 1.5T and 3.0T combine morphological T2W imaging with functional sequences (perfusion imaging, diffusion imaging, spectroscopy) using high-resolution phased array pelvic coils or « combined » coils (added endorectal coil). To promote acceptance by clinicians and increased access to patients, the indications for prostate MR must be better defined (and provide useful data to urologists), the cost must be reduced, and results must be more reproducible and standardized.

[1]  Heinz-Peter Schlemmer,et al.  MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. , 2006, European urology.

[2]  Jelle O. Barentsz,et al.  Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal–pelvic phased-array coils , 2007, European Radiology.

[3]  B. K. Park,et al.  Diffusion-Weighted Imaging of the Prostate at 3 T for Differentiation of Malignant and Benign Tissue in Transition and Peripheral Zones: Preliminary Results , 2007, Journal of computer assisted tomography.

[4]  Yuri Kitamura,et al.  Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. , 2006, AJR. American journal of roentgenology.

[5]  P. Carroll,et al.  Imaging for recurrent prostate cancer. , 2000, Radiologic clinics of North America.

[6]  N. Grenier,et al.  Thérapies par ultrasons focalisés , 2007 .

[7]  A. Shibata The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens , 1999, Cancer.

[8]  Piotr Kozlowski,et al.  Diffusion-weighted MRI in prostate cancer -- comparison between single-shot fast spin echo and echo planar imaging sequences. , 2008, Magnetic resonance imaging.

[9]  M. Terris,et al.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. , 1989, The Journal of urology.

[10]  T. Stamey,et al.  Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate , 1990, Cancer.

[11]  A. D'Amico,et al.  Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. , 2000, The Journal of urology.

[12]  François Bénard,et al.  Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. , 2007, European journal of cancer.

[13]  D. Ornstein,et al.  Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores. , 2000, The Journal of urology.

[14]  Olivier Rouvière,et al.  Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor--correlation with biopsy findings. , 2004, Urology.

[15]  A. D'Amico,et al.  Transperineal magnetic resonance image guided prostate biopsy. , 2000, The Journal of urology.

[16]  K. Ali,et al.  PSA doubling time predicts the outcome after active surveillance in screening‐detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section , 2006 .

[17]  A. D'Amico,et al.  Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate‐specific antigen failure , 2007, Cancer.

[18]  Sheng Xu,et al.  Closed-Loop Control in Fused MR-TRUS Image-Guided Prostate Biopsy , 2007, MICCAI.

[19]  E. Bergstralh,et al.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate‐specific antigen testing: 15‐year outcome , 2005, BJU international.

[20]  L. Curiel,et al.  Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. , 2004, Urology.

[21]  D. Portalez,et al.  IRM et bilan d’extension du cancer de la prostate , 2006 .

[22]  Laura Curiel,et al.  Control of prostate cancer by transrectal HIFU in 227 patients. , 2007, European urology.

[23]  J R Thornbury,et al.  Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. , 1996, AJR. American journal of roentgenology.

[24]  Rosalie Nolley,et al.  The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? , 2004, The Journal of urology.

[25]  P. Dettmar,et al.  Limited value of endorectal magnetic resonance imaging and transrectal ultrasonography in the staging of clinically localized prostate cancer , 2001, BJU international.

[26]  J Kurhanewicz,et al.  The prostate: MR imaging and spectroscopy. Present and future. , 2000 .

[27]  Koji Okihara,et al.  Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. , 2002, Urology.

[28]  J. Horti,et al.  Prostate cancer screening. , 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[29]  J. Severens,et al.  Patient Selection for Magnetic Resonance Imaging of Prostate Cancer , 2001, European Urology.

[30]  Liang Cheng,et al.  Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens , 2005, Modern Pathology.

[31]  Rémi Souchon,et al.  Transrectal high-intensity focused ultrasound ablation of prostate cancer: effective treatment requiring accurate imaging. , 2007 .

[32]  Silvia D. Chang,et al.  Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. , 2002, Radiology.

[33]  T. Stamey,et al.  Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. , 1989, The Journal of urology.

[34]  D. Portalez,et al.  L’IRM de la prostate sans antenneendorectale : une nouvelle exception française ? , 2008 .

[35]  A. Villers,et al.  Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. , 2006, The Journal of urology.

[36]  Michael W Kattan,et al.  Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. , 2007, Radiology.

[37]  P. Carroll,et al.  Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. , 2004, Radiology.

[38]  W. Hop,et al.  Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. , 1998, The Journal of urology.

[39]  Haiqun Lin,et al.  Radial Distance of Extraprostatic Extension Measured by Ocular Micrometer is an Independent Predictor of Prostate-specific Antigen Recurrence: A New Proposal for the Substaging of pT3a Prostate Cancer , 2007, The American journal of surgical pathology.

[40]  P. Carroll,et al.  Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. , 2004, Radiology.

[41]  Thomas Hambrock,et al.  Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. , 2007, Radiology.

[42]  Xavier Leroy,et al.  Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings , 2009, European Radiology.

[43]  Seong Ho Park,et al.  Wash‐in rate on the basis of dynamic contrast‐enhanced MRI: Usefulness for prostate cancer detection and localization , 2005, Journal of magnetic resonance imaging : JMRI.

[44]  R Alagappan,et al.  Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. , 1997, Radiology.

[45]  B. K. Park,et al.  Comparison of Phased-Array 3.0-T and Endorectal 1.5-T Magnetic Resonance Imaging in the Evaluation of Local Staging Accuracy for Prostate Cancer , 2007, Journal of computer assisted tomography.

[46]  R. Stephenson,et al.  Isolated seminal vesicle invasion imparts better outcomes after radical retropubic prostatectomy for clinically localized prostate cancer: prognostic stratification of pt3b disease by nodal and margin status. , 2005, Urology.

[47]  D. Jung,et al.  Preoperative MR imaging in the evaluation of seminal vesicle invasion in prostate cancer: Pattern analysis of seminal vesicle lesions , 2008, Journal of magnetic resonance imaging : JMRI.

[48]  S B Malkowicz,et al.  Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. , 2001, The Journal of urology.

[49]  Olivier Rouvière,et al.  Prostate MR imaging at high-field strength: evolution or revolution? , 2006, European Radiology.

[50]  M. Lock,et al.  Controversies in prostate cancer staging implementation at a tertiary cancer center. , 2006, The Canadian journal of urology.

[51]  J R Thornbury,et al.  Prostate cancer staging: should MR imaging be used?--A decision analytic approach. , 2000, Radiology.

[52]  Ying Lu,et al.  Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experience. , 2008, Radiology.

[53]  J. Folkman,et al.  Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. , 2001, The Journal of urology.

[54]  Olivier Rouvière,et al.  Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? , 2007, European Radiology.

[55]  H. Shinmoto,et al.  Prostate cancer screening: The clinical value of diffusion‐weighted imaging and dynamic MR imaging in combination with T2‐weighted imaging , 2007, Journal of magnetic resonance imaging : JMRI.

[56]  A. Hemal,et al.  Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut‐off value to predict malignancy of the peripheral zone , 2007, NMR in biomedicine.

[57]  X. Rébillard,et al.  Conditions de réalisation et schéma de ponctions lors d'une première série de biopsies prostatiques , 2004 .

[58]  A. Villers,et al.  Dynamic Contrast-Enhanced MRI for Preoperative Identification of Localised Prostate Cancer , 2007 .

[59]  J Alfred Witjes,et al.  Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. , 2005, Radiology.

[60]  M. Melamed,et al.  Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate--a 4-year experience. , 2007, Urology.

[61]  Michael W Kattan,et al.  Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. , 2004, Radiology.

[62]  Olivier Rouvière,et al.  Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging , 2003, European Radiology.

[63]  Benjamin M Yeh,et al.  Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. , 2008, Radiology.

[64]  P. Scardino,et al.  Is tumor volume an independent prognostic factor in clinically localized prostate cancer? , 2004, The Journal of urology.

[65]  M. Kattan,et al.  Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. , 1998, Human pathology.

[66]  Peter L Choyke,et al.  Imaging prostate cancer: a multidisciplinary perspective. , 2007, Radiology.

[67]  Jason A Koutcher,et al.  Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings. , 2008, Radiology.

[68]  J. Srigley Key issues in handling and reporting radical prostatectomy specimens. , 2009, Archives of pathology & laboratory medicine.

[69]  Fiona J Gilbert,et al.  Reading protocol for dynamic contrast-enhanced MR images of the breast: sensitivity and specificity analysis. , 2005, Radiology.

[70]  Rodolfo Montironi,et al.  Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. , 2007, European urology.

[71]  Jelle O. Barentsz,et al.  Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis , 2002, European Radiology.

[72]  B. Guillonneau,et al.  Preoperative and intraoperative risk factors for side-specific positive surgical margins in laparoscopic radical prostatectomy for prostate cancer. , 2007, European urology.

[73]  Liang Cheng,et al.  The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  P. Carroll,et al.  Multiparametric magnetic resonance imaging in prostate cancer: present and future , 2008, Current opinion in urology.

[75]  Clare Allen,et al.  MR imaging of prostate after treatment with high-intensity focused ultrasound. , 2008, Radiology.

[76]  Jason A Koutcher,et al.  Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. , 2005, Radiology.

[77]  L. Lemaitre,et al.  Prostate cancer computer-assisted diagnosis software using dynamic contrast-enhanced MRI , 2007, 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[78]  Peter Guion,et al.  Initial clinical experience with real‐time transrectal ultrasonography‐magnetic resonance imaging fusion‐guided prostate biopsy , 2008, BJU international.

[79]  T. Stamey,et al.  PATTERNS OF PROGRESSION IN PROSTATE CANCER , 1986, The Lancet.

[80]  A. Hemal,et al.  Original contributions Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level , 2006 .

[81]  Laurent Lemaitre,et al.  Cancer de la prostate : les aspects cliniques, biologiques et histopathologiques utiles au radiologue , 2006 .

[82]  M. Roobol,et al.  The value of an additional hypoechoic lesion‐directed biopsy core for detecting prostate cancer , 2008, BJU international.

[83]  P. Carroll,et al.  Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. , 1999, Radiology.

[84]  L. Collette,et al.  Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). , 2006, European journal of cancer.

[85]  Robert W Veltri,et al.  Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. , 2003, The Journal of urology.

[86]  Stefan A Reinsberg,et al.  Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. , 2007, AJR. American journal of roentgenology.

[87]  J. McNeal,et al.  Patterns of spread of adenocarcinoma in the prostate as related to cancer volume , 2001, The Prostate.

[88]  Clare Allen,et al.  How good is MRI at detecting and characterising cancer within the prostate? , 2006, European urology.

[89]  K. Taari,et al.  Prostatic MR imaging: Accuracy in differentiating cancer from other prostatic disorders , 2001, Acta radiologica.

[90]  H. Huisman,et al.  Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. , 2006, Radiology.

[91]  O. Rouvière,et al.  Détection par IRM des récidives locales du cancer de prostate après traitement par ultrasons focalisés de haute intensité (HIFU) transrectaux : étude préliminaire , 2008 .

[92]  G. Lightbody,et al.  The effect of frequency band on quantitative EEG measures in neonates with Hypoxic-ischaemic encephalopathy , 2007, 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[93]  L. Holmberg,et al.  The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. , 1997, Urology.

[94]  Fiona J Gilbert,et al.  Evaluation of a prospective scoring system designed for a multicenter breast MR imaging screening study. , 2006, Radiology.

[95]  P. Carroll,et al.  Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. , 2004, AJR. American journal of roentgenology.

[96]  M. Kattan,et al.  Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. , 2005, Radiology.